Participants 18 years of age or older (≥ 19 years old for participants in South Korea).
Histologically or cytologically confirmed advanced malignant solid tumors, who have progressed on, are intolerant to or are ineligible for standard therapy, or have no standard treatment options.
Participant tumors are methylthioadenosine phosphorylase (MTAP)-deficient.
Adequate organ function
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
All participants must provide a pretreatment tumor tissue sample.
You may not be if
Participants with plans to breastfeed during the study period or within 7 days following the last dose of study intervention.
Have not recovered (ie, returned to Grade 1 or baseline) from clinically significant adverse events (AEs) due to a previously administered agent or a previous intervention as assessed by the investigator.
Active second malignancy. Individuals with a history of malignancy who have been completely treated with no evidence of active cancer for 5 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence may be enrolled.
Requirement for ongoing therapy with any prohibited medications .
Prior therapy with a protein arginine methyltransferase 5 (PRMT5) inhibitor or methionine adenosine transferase 2a (MAT2A) inhibitor.
Have serious infection requiring antibiotics within 14 days prior to the first dose.
Uncontrolled concurrent diseases
Clareo Health | Study of GS-2426 in Participants With Advanced Solid Tumors
